• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Ascletis Completes Phase 3 Enrollment for ASC40 in Acne Treatment

    PR NEWSWIRE

    Sagimet Bio Announces Presentations At AASLD Liver Meeting 2024

    GLOBENEWSWIRE

    Sagimet Receives FDA Breakthrough Designation for Denifanstat

    GLOBENEWSWIRE

    Sagimet to Participate in Two Upcoming Investor Conferences

    GLOBENEWSWIRE

    Sagimet Biosciences Reports Q2 2024 Financial Results And Corporate Updates

    GLOBENEWSWIRE

    Sagimet Presents ITT And F3 Data From Phase 2b FASCINATE-2 At EASL 2024

    GLOBENEWSWIRE

    Sagimet Biosciences Reports Q1 2024 Financials, Corporate Updates

    GLOBENEWSWIRE

    Sagimet Oral Data From FASCINATE-2 Study At EASL 2024

    GLOBENEWSWIRE

    Ascletis pulls FXR agonist from pipeline over phase 2 data

    FIERCE BIOTECH

    Sagimet Announces Completion of Phase 1 Study with FASN Inhibitor Denifanstat

    GLOBENEWSWIRE

    Sagimet Reports Full Year 2023 Financial Results and Provides Corporate Updates

    GLOBENEWSWIRE

    Gannex`s Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

    PR NEWSWIRE

    Ascletis Announces Initiation of Phase III Clinical Trial of ASC40

    PR NEWSWIRE

    Sagimet Biosciences Presents Positive Phase 2b FASCINATE-2 Clinical Trial

    GLOBENEWSWIRE

    Sagimet to Present Data from Ph2b Trial of Denifanstat in NASH at EASL 2023

    GLOBENEWSWIRE

    Ascletis Announces Completion of 180 Patient Enrollment for Ph II Clinical Trial

    PRNEWSWIRE

    Sagimet Biosciences Announces Positive Phase 2b Trial Data with Denifanstat

    BUSINESSWIRE

    Sagimet Announces Late-Breaking, Oral and Poster Presentations for Denifanstat

    BUSINESSWIRE

    Sagimet Announces Completion of Patient Enrollment in P2b Trial with TVB-2640

    BUSINESSWIRE

    Sagimet Bio Announces Oral Presentation on Denifanstat in NASH

    BUSINESSWIRE

    Sagimet Biosciences Announces Presentation of Additional PII Data on Denifanstat

    BUSINESSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.